Drug-coated balloons (DCB), also referred to as drug-eluting balloons, are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia caused by vessel trauma from the balloon angioplasty. Find news and video content on DCBs
Last updated on September 10, 2020
News | Drug-Eluting Balloons | March 12, 2021
Five-year ILLUMENATE EU RCT and Pivotal Data Confirm Safety of Philips Stellarex Low-dose Drug-coated Balloon
March 12, 2021 — Philips Healthcare announced the final, five-year results of two major randomized controlled trials
News | Drug-Eluting Balloons | November 03, 2020
November 3, 2020 — The U.S.
News | Drug-Eluting Balloons | October 18, 2020
Drug-coated Balloon for Challenging Below-the-Knee Disease Shows Promise in Patients with Critical Limb Ischemia
October 18, 2020 – The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the s
Videos | Drug-Eluting Balloons | September 09, 2020
Feature | Drug-Eluting Balloons | August 06, 2020 | Dave Fornell, Editor
News | Drug-Eluting Balloons | July 07, 2020
July 7, 2020 – MedAlliance announced enrollment of the first patient in its study of Selution SLR 0.014...
News | Drug-Eluting Balloons | June 19, 2020
June 19, 2020 — iVascular SLU announced the global launch of Essential Pro, a novel coronary artery ...
News | Drug-Eluting Balloons | June 18, 2020
June 17, 2020 — MedAlliance announced its second CE mark approval for its Selution SLR 0.014 percutaneous translumina
News | Drug-Eluting Balloons | May 28, 2020
May 28, 2020 – MedAlliance has announced the award of its second European CE mark clearance for its Selution SLR 0.01
News | Drug-Eluting Balloons | November 14, 2019
November 7, 2019 — The IN.PACT Arteriovenous (AV) Access randomized trial evaluating the safety and effectiveness of